A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.
dc.contributor.author | Sivalingam, Vanitha | |
dc.contributor.author | McVey, R | |
dc.contributor.author | Gilmour, K | |
dc.contributor.author | Ali, S | |
dc.contributor.author | Roberts, C | |
dc.contributor.author | Renehan, Andrew G | |
dc.contributor.author | Kitchener, Henry C | |
dc.contributor.author | Crosbie, Emma J | |
dc.date.accessioned | 2015-09-17T11:09:57Z | en |
dc.date.available | 2015-09-17T11:09:57Z | en |
dc.date.issued | 2015-02-26 | en |
dc.identifier.citation | A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. 2015, 385 Suppl 1:S90 Lancet | en |
dc.identifier.issn | 1474-547X | en |
dc.identifier.pmid | 26312913 | en |
dc.identifier.doi | 10.1016/S0140-6736(15)60405-6 | en |
dc.identifier.uri | http://hdl.handle.net/10541/577426 | en |
dc.description.abstract | Metformin use is associated with reduced cancer risk in several observational studies of patients with type 2 diabetes. Results from preclinical studies in endometrial cancer show that metformin reduces cellular proliferation by inhibition of the PI3K-AKT-mTOR pathway. We tested the hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrial endometrioid adenocarcinoma. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Lancet (London, England) | en |
dc.title | A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. | en |
dc.type | Article | en |
dc.contributor.department | Institute of Cancer Sciences, University of Manchester, Manchester, UK | en |
dc.identifier.journal | Lancet | en |
html.description.abstract | Metformin use is associated with reduced cancer risk in several observational studies of patients with type 2 diabetes. Results from preclinical studies in endometrial cancer show that metformin reduces cellular proliferation by inhibition of the PI3K-AKT-mTOR pathway. We tested the hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrial endometrioid adenocarcinoma. |